Longitude Capital Partners II, LLC → Kala Pharmaceuticals, Inc. KALA

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 6/100

Passive Schedule 13G filer baseline

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-10-15

DTC 1.00

539,414 shares short · -60.3% vs prior

Other 13D/G Filings on Kala Pharmaceuticals, Inc.

Filed	Form	Filer	Stake	Shares
2026-10-19	SCHEDULE 13G	Labkowski Nachum	—	—	view →
2026-07-02	SCHEDULE 13D/A	Lazar David E.	3.90%	719,404	view →
2025-10-01	SCHEDULE	SR ONE CAPITAL MANAGEMENT, LLC	5.50%	411,000	view →
2022-05-25	SC	RA CAPITAL MANAGEMENT, L.P.	—	—	view →
2022-04-01	SC	RA CAPITAL MANAGEMENT, L.P.	—	—	view →

Other Filings by Longitude Capital Partners II, LLC

Filed	Form	Issuer	Stake	Shares
2023-03-16	SC	Aptinyx Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →